<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from N/A to N/A
--- ---
Commission File No. 814-82
TECHNOLOGY FUNDING VENTURE PARTNERS V, AN AGGRESSIVE GROWTH FUND, L.P.
----------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 94-3094910
- ------------------------------- ----------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2000 Alameda de las Pulgas, Suite 250
San Mateo, California 94403
- --------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(650) 345-2200
----------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
--- ---
No active market for the units of limited partnership interests
("Units") exists, and therefore the market value of such Units cannot be
determined.
<PAGE>
I. FINANCIAL INFORMATION
Item 1. Financial Statements
BALANCE SHEETS
- --------------
<TABLE>
<CAPTION>
(unaudited)
March 31, December 31,
2000 1999
------------ ------------
<S> <C> <C>
ASSETS
Equity investments (cost basis of
$19,579,296 and $19,844,552 at
2000 and 1999, respectively) $45,921,355 39,181,437
Notes receivable, net (cost basis of
$5,181,578 and $2,569,534 at 2000
and 1999, respectively) 5,181,578 2,569,534
---------- ----------
Total investments 51,102,933 41,750,971
Cash and cash equivalents 14,115,339 6,356,856
Other assets 10,075 3,097
---------- ----------
Total assets $65,228,347 48,110,924
========== ==========
LIABILITIES AND PARTNERS' CAPITAL
Accounts payable and accrued expenses $ 67,073 56,565
Distributions payable to Limited and
General Partners -- 5,412,980
Due to related parties 1,000,764 27,609
---------- ----------
Total liabilities 1,067,837 5,497,154
Commitments, contingencies and
subsequent events (Notes 2, 3, 7 and 8)
Partners' capital:
Limited Partners (400,000 units outstanding) 59,065,654 41,595,012
General Partners 5,094,856 1,018,758
---------- ----------
Total partners' capital 64,160,510 42,613,770
---------- ----------
Total liabilities and partners' capital $65,228,347 48,110,924
========== ==========
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
STATEMENTS OF OPERATIONS (unaudited)
- -----------------------------------
<TABLE>
<CAPTION>
For the Three Months Ended March 31
-----------------------------------
2000 1999
--------- ---------
<S> <C> <C>
Income:
Notes receivable interest $ 461,616 1,230
Short-term interest income 71,515 20
--------- ---------
Total income 533,131 1,250
Costs and expenses:
Management fees 61,972 72,395
Individual General Partners'
compensation 6,497 7,169
Operating expenses:
Investment operations 97,553 103,810
Administrative and investor services 142,313 147,323
Professional fees 17,959 14,869
Computer services 39,708 30,721
Interest expense -- 7,031
---------- ---------
Total operating expenses 297,533 303,754
---------- ---------
Total costs and expenses 366,002 383,318
---------- ---------
Net operating income (loss) 167,129 (382,068)
Net realized gain sales of equity
investments 14,105,324 2,238,762
Realized gain from venture capital
limited partnership investments 219,012 82,496
---------- ---------
Net realized income 14,491,465 1,939,190
Change in net unrealized
fair value of equity
investments 7,005,174 3,987,178
Net unrealized gain on foreign currency
transaction 50,101 --
---------- ---------
Net income $21,546,740 5,926,368
========== =========
Net income per Unit $ 43.68 11.89
========== =========
</TABLE>
See accompanying notes to unaudited financial statements
<PAGE>
STATEMENTS OF CASH FLOWS (unaudited)
- -----------------------------------
<TABLE>
<CAPTION>
For the Three Months Ended March 31,
------------------------------------
2000 1999
--------- ---------
<S> <C> <C>
Cash flows from operating activities:
Interest income received $ 83,875 160
Cash paid to vendors (99,523) (126,410)
Cash paid to related parties (259,794) (738,266)
Interest paid -- (7,031)
---------- ---------
Net cash used by
operating activities (275,442) (871,547)
---------- ---------
Cash flows from investing activities:
Proceeds from sales of equity
investments 16,184,476 1,090,338
Purchase of equity investments (840,445) (100,066)
Notes receivable issued (2,225,000) --
Repayments of notes receivable 58,761 --
Distributions from venture capital
limited partnership investments 219,012 --
---------- ---------
Net cash provided by investing
activities 13,396,804 990,272
---------- ---------
Cash flows from financing activities:
Repayment of short-term borrowings -- (120,200)
Distributions to Limited and General
Partners (5,412,980) --
---------- ---------
Net cash used by financing activities (5,412,980) (120,200)
---------- ---------
Effect of exchange rate changes on cash
and cash equivalents 50,101 --
---------- ---------
Net increase (decrease) in cash and
cash equivalents 7,758,483 (1,475)
Cash and cash equivalents at
beginning of year 6,356,856 15,850
---------- ---------
Cash and cash equivalents
at March 31 $14,115,339 14,375
========== =========
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
STATEMENTS OF CASH FLOWS (unaudited) (continued)
- -----------------------------------------------
<TABLE>
<CAPTION>
For the Three Months Ended March 31,
------------------------------------
2000 1999
--------- ---------
<S> <C> <C>
Reconciliation of net income
to net cash used by
operating activities:
Net income $21,546,740 5,926,368
Adjustments to reconcile net income
to net cash used by
operating activities:
Net realized gain from
sales of equity investments (14,105,324) (2,238,762)
Realized gain from venture
capital limited partnership
investments (219,012) (82,496)
Change in net unrealized fair
value of equity investments (7,005,174) (3,987,178)
Net unrealized gain on foreign
currency transaction (50,101) --
Changes in:
Accrued interest on notes receivable (449,256) (1,090)
Accounts payable and accrued
expenses 10,508 (14,138)
Due to related parties 3,155 (470,116)
Other (6,978) (4,135)
---------- ---------
Net cash used by operating activities $ (275,442) (871,547)
========== =========
Supplemental schedule of non-cash
investing activity:
Investment sales receivable $ -- 1,473,366
========== =========
Non-cash exercise of warrants $ 57,679 --
========== =========
Investment purchase costs payable to
affiliated partnership $ 970,000 --
========== =========
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
NOTES TO FINANCIAL STATEMENTS (unaudited)
- ----------------------------------------
1. General
-------
In the opinion of the Managing General Partners, the Balance Sheets as of
March 31, 2000, and December 31, 1999, and the related Statements of
Operations and Statements of Cash Flows for the three months ended March
31, 2000 and 1999, reflect all adjustments which are necessary for a fair
presentation of the financial position, results of operations and cash
flows for such periods. These statements should be read in conjunction
with the Annual Report on Form 10-K for the year ended December 31, 1999.
The following notes to financial statements for activity through March 31,
2000, supplement those included in the Annual Report on Form 10-K.
Allocation of income and loss to Limited and General Partners is based on
cumulative income and loss. Adjustments, if any, are reflected in the
current quarter balances.
Partners' Capital Reclassification
- ----------------------------------
Commencing in the fourth quarter of 1999, the Partnership is including the
change in net unrealized fair value of investments in the profits and
losses allocated to partners' capital accounts based on a reevaluation of
the Partnership Agreement. The allocations of the net unrealized fair
value increase (decrease) from cost of investments, and resulting
reclassifications, were determined by applying the provisions of the
Partnership Agreement from the inception of the Partnership. The
reclassification has no effect on total partners' capital or the
Partnership's net income or loss for any period. The reclassifications
resulting from the reevaluation of the Partnership Agreement have the
effect of accelerating the allocation of profits or losses to partners'
capital accounts and, as a result, may permit the acceleration of
distributions to Partners to the extent allowable under the Partnership
Agreement.
The allocation of the net unrealized fair value increase reclassified as of
March 31, 1999 follows:
Net Unrealized
Fair Value
Increase
Limited General From Cost of
Partners Partners Investments Total
-------- -------- -------------- ---------
Partners' capital,
March 31, 1999,
before reclassification $22,357,229 18,922 20,400,684 42,776,835
Allocation of net
unrealized fair value
increase from cost 19,241,995 1,158,689 (20,400,684) --
---------- --------- ---------- ----------
Partners' capital,
March 31, 1999,
as reclassified $41,599,224 1,177,611 -- 42,776,835
========== ========= ========== ==========
2. Related Party Transactions
--------------------------
Related party costs are included in costs and expenses shown on the
Statements of Operations. Related party costs for the three months ended
March 31, 2000 and 1999, were as follows:
<TABLE>
<CAPTION>
2000 1999
-------- --------
<S> <C> <C>
Management fees $ 61,972 72,395
Reimbursable operating expenses 194,480 188,586
Individual General Partners' compensation 6,497 7,169
</TABLE>
Certain reimbursable expenses have been accrued based upon interim
estimates prepared by the Managing General Partners and are adjusted to
actual cost periodically. There were $9,924 and $71,170 due from related
parties at March 31, 2000 and December 31, 1999, respectively, for such
reimbursable expenses.
Amounts payable for management fees were $40,688 and $26,283 at March 31,
2000, and December 31, 1999, respectively.
At December 31, 1999, the Partnership had a payable of $72,496 for
investment sales proceeds due to an affiliated partnership. These monies
were paid in the first quarter of 2000. At March 31, 2000, the Partnership
had a payable of $970,000 for investment purchase costs due to an
affiliated partnership. The monies were paid in May 2000.
Officers of the Managing General Partners occasionally receive stock
options as compensation for serving on the Boards of Directors of portfolio
companies. It is the Managing General Partners' policy that all such
compensation be transferred to the investing partnerships. If the options
are non-transferable, they are not recorded as an asset of the Partnership.
Any profit from the exercise of such options will be transferred if and
when the options are exercised and the underlying stock is sold by the
officers. Any such profit is allocated amongst the Partnership and
affiliated partnerships based upon their proportionate investments in the
portfolio company. At March 31, 2000, the Partnership and affiliated
partnerships had an indirect interest in non-transferable Endocare, Inc.
and Physiometrix, Inc. options with a fair market value of $488,145.
<PAGE>
3. Equity Investments
------------------
<TABLE>
A full listing of the Partnership's equity investments at December 31, 1999, is in the 1999
Annual Report on Form 10-K. Activity from January 1 through March 31, 2000, consisted of:
<CAPTION>
January 1 through
March 31, 2000
Principal -------------------
Amount or
Investment Shares as of Cost Fair
Industry/Company Position Date March 31, 2000 Basis Value
- ---------------- -------- ---------- -------------- ----- -----
<S> <C> <C> <C> <C> <C>
Balance at January 1, 2000 $19,844,552 39,181,437
---------- ----------
Significant changes:
Biomedical
- ----------
Axys Common
Pharmaceuticals, Inc. shares 1995 37,855 0 137,679
Biotechnology
- -------------
CV Therapeutics, Common 1994-
Inc. shares 1995 0 (322,800) (407,741)
Communications
- --------------
Efficient Networks, Common
Inc. shares 1999 0 (75,254) (64,487)
eoSports, Incorporated Preferred
(a) shares 2000 652,000 652,000 652,000
Women.com Networks, Common 1996-
Inc. (a) shares 1999 204,384 0 (506,525)
Computer Systems and Software
- -----------------------------
Pilot Network Common 1996-
Services, Inc. shares 1999 0 (284,553) (4,259,590)
Medical
- -------
ADESSO Specialty
Services Organization, Preferred 1995-
Inc. (a) (b) shares 1997 808,543 188,446 6,885,985
ADESSO Specialty Preferred share
Services Organization, warrant at $1.00;
Inc. (a) (b) expiring 2001 1996 68,704 0 577,113
Endocare, Common 1996-
Inc. (b) shares 1999 49,764 0 537,451
Oxford Common
GlycoSciences Plc shares 1993 0 (999,927) (1,772,432)
Pharmadigm, Preferred 1993-
Inc. (a) shares 1998 733,815 0 (1,042,018)
Pharmos Common
Corporation shares 1995 0 (45,248) (122,170)
Physiometrix, Common 1996-
Inc. (b) shares 2000 295,769 57,858 4,705,864
Resolution Sciences Preferred
Corporation (a) shares 2000 485,000 970,000 970,000
Valentis, Common 1994-
Inc. shares 1995 196,274 (407,767) (552,342)
Venture Capital Limited Partnership Investments
- -----------------------------------------------
Various Limited
Partnership
Interests various $1,053,431 0 1,008,615
---------- ---------
Total significant changes during the three
months ended March 31, 2000 (267,245) 6,747,402
Other changes, net 1,989 (7,484)
---------- ----------
Total equity investments at March 31, 2000 $19,579,296 45,921,355
========== ==========
Legend and footnotes:
(a) Equity securities acquired in a private placement transaction;
resale may be subject to certain selling restrictions.
(b) Portfolio company is an affiliate of the Partnership;
resale may be subject to certain selling restrictions.
</TABLE>
Marketable Equity Securities
- ----------------------------
At March 31, 2000, and December 31, 1999, marketable equity securities had
aggregate costs of $2,168,771 and $3,856,351, respectively, and aggregate
market values of $9,228,109 and $11,037,866, respectively. The net
unrealized gains at March 31, 2000 and December 31, 1999 included gross
gains of $7,271,374 and $7,545,809, respectively.
ADESSO Specialty Services Organization, Inc.
- --------------------------------------------
In March 2000, the Partnership purchased 11,217 Series E Preferred shares
for $188,446. The pricing of this round, in which third parties
participated, indicated a $7,274,652 increase in the fair value of the
Partnership's investment in the company's preferred shares and preferred
share warrants.
CV Therapeutics, Inc.
- ---------------------
In January 2000, the Partnership sold its entire investment in the company
for proceeds of $437,508 and realized a gain of $114,708.
Efficient Networks, Inc.
- ------------------------
In February, 2000, the Partnership sold its entire investment in the
company for proceeds of $109,365 and realized a gain of $34,111.
eoSports, Incorporated
- ----------------------
In March 2000, the Partnership purchased 652,000 Series A Preferred shares
in the company for $652,000.
Oxford GlycoSciences Plc
- ------------------------
During the first quarter of 2000, the Partnership sold its entire
investment in the company for proceeds of $8,108,374 and realized a gain of
$7,108,447.
Pharmadigm, Inc.
- ----------------
In March 2000, the company completed a new round of financing in which the
Partnership did not participate. The pricing of this round, in which third
parties participated, indicated a $1,046,833 decrease in the fair value of
the Partnership's investment.
Pharmos Corporation
- -------------------
In January 2000, the Partnership sold its entire investment in the company
for proceeds of $191,382 and realized a gain of $146,134.
Physiometrix, Inc.
- ------------------
In March 2000, the Partnership net exercised a common share warrant for
13,525 shares at $6.60 each and received 8,748 common shares with a cost
basis of $57,858. The Partnership realized a gain of $57,679 on the
warrant exercise.
Subsequent to March 31, 2000, the fair value of the Partnership's
investment in the company decreased by $1,955,920 as a result of a decrease
in the publicly traded market price on May 8, 2000.
Pilot Network Services, Inc.
- ----------------------------
During the first quarter of 2000, the Partnership sold its entire
investment in the company for proceeds of $5,324,389 and realized a gain of
$5,039,836.
Resolution Sciences Corporation
- -------------------------------
In February 2000, the Partnership purchased 485,000 Series C Preferred
shares for $970,000.
Simione Central Holdings, Inc.
- ------------------------------
In March 2000, the company's shareholders approved a one-for-five reverse
stock split in order to meet requirements to maintain the company's listing
on the Nasdaq National Market.
Valentis, Inc.
- --------------
In March 2000, the Partnership sold 105,000 common shares in the company
for proceeds of $2,013,434 and realized a gain of $1,605,667.
Subsequent to March 31, 2000, the fair value of the Partnership's
investment in the company decreased by $718,952 as a result of a decrease
in the publicly traded market price on May 8, 2000.
Venture Capital Limited Partnerships
- ------------------------------------
The Partnership received cash distributions totaling $219,012 from El
Dorado Ventures III, L.P., Colorado Venture Management IV and Spectrum
Equity Investors limited partnerships. These distributions were recorded
as realized gains. The Partnership recorded a $1,008,615 increase in fair
value as a result of a net increase in the fair value of the underlying
investments of the partnerships.
Other Equity Investments
- ------------------------
Other significant changes reflected above relate to market value
fluctuations or the elimination of a discount relating to selling
restrictions for publicly-traded portfolio companies. Portions of the
Partnership's Simione Central Holdings, Inc. and Women.com Networks, Inc.
investments are restricted.
Subsequent to March 31, 2000, the fair value of the Partnership's
investment in Women.com Networks, Inc. decreased by $765,766 as a result of
a decrease in the publicly traded market price on May 8, 2000.
4. Notes Receivable
----------------
Activity from January 1 through March 31 consisted of:
<TABLE>
<CAPTION>
2000
---------
<S> <C>
Balance at January 1 $2,569,534
Notes receivable issued 2,225,000
Repayments of notes receivable (58,761)
Change in interest receivable 445,805
---------
Balance at March 31 $5,181,578
=========
</TABLE>
The interest rate on notes receivable at March 31, 2000 ranged from 8.5% to
50%. All notes are due on demand.
There were no notes receivable outstanding at January 1 and March 31, 1999.
5. Cash and Cash Equivalents
-------------------------
Cash and cash equivalents at March 31, 2000, and December 31, 1999
consisted of:
<TABLE>
<CAPTION>
2000 1999
-------- ------
<S> <C> <C>
Demand accounts $ 140,770 3,419,708
Money-market accounts 13,974,569 2,937,148
---------- ---------
Total $14,115,339 6,356,856
========== =========
</TABLE>
6. Short-Term Borrowings
---------------------
The Partnership has a borrowing account with a financial institution. At
March 31, 2000, the borrowing capacity of this account, which fluctuates
based on collateral value, was $1,261,814 and there were no outstanding
borrowings. Interest is charged at the prime rate plus one-half percent.
The Partnership's investments in Axys Pharmaceuticals, Inc. and Valentis,
Inc. are pledged as collateral.
7. Distributions
-------------
In the first quarter of 2000, a tax distribution of $5,412,980 declared in
1999 was paid to General and Limited Partners. Subsequent to March 31,
2000, a quarterly tax distribution was declared and paid to General
Partners totaling $1,935,574.
8. Commitments and Contingencies
-----------------------------
The Partnership is a party to financial instruments with off-balance-sheet
risk in the normal course of its business. Generally, these instruments
are commitments for future equity fundings, venture capital limited
partnership investments, equipment financing commitments, or accounts
receivable lines of credit that are outstanding but not currently fully
utilized. As they do not represent current outstanding balances, these
unfunded commitments are properly not recognized in the financial
statements. At March 31, 2000 the Partnership had the following unfunded
commitments:
<TABLE>
<CAPTION>
TYPE
- ----
<S> <C>
Notes receivable $ 225,000
Equity investments 200,000
Equipment lease guarantees 737,000
Venture capital limited partnership investments 21,975
---------
Total $1,183,975
=========
</TABLE>
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Liquidity and Capital Resources
- -------------------------------
During the three months ended March 31, 2000, net cash used by operating
activities totaled $275,442. The Partnership paid management fees of
$47,567 to the Managing General Partners and reimbursed related parties for
operating expenses of $133,234. The Partnership also paid investment sales
proceeds of $72,496 to an affiliated partnership. In addition, $6,497 was
paid to the Individual General Partners as compensation for their services
and other operating expenses of $99,523 were paid. Interest income of
$83,875 was received.
During the three months ended March 31, 2000, the Partnership funded equity
investments of $840,445 to portfolio companies in the communications and
medical industries; additional equity investment purchase costs of $970,000
were payable to an affiliated partnership at March 31, 2000. Proceeds from
sales of equity investments provided cash of $16,184,476. The Partnership
funded $2,225,000 in notes receivable to portfolio companies in the
computer systems and software and industrial/business automation
industries. Repayments of notes receivable were $58,761. The Partnership
received cash distributions from venture capital limited partnerships
totaling $219,012. As of March 31, 2000, the Partnership's unfunded
commitments totaled $1,183,975 as discussed in Note 8 to the financial
statements. Tax distributions totaling $5,412,980 were paid to General and
Limited Partners.
The Partnership has a borrowing account with a financial institution. The
borrowing capacity of this account, which fluctuates based on collateral
value, was $1,261,814 and there were no outstanding borrowings at March 31,
2000. The Partnership's investments in Axys Pharmaceuticals, Inc. and
Valentis, Inc. are pledged as collateral.
Cash and cash equivalents at March 31, 2000, were $14,115,339. Cash
reserves, future interest income on short-term investments and proceeds
from investment sales are expected to be adequate to fund Partnership
operations through the next twelve months. Subsequent to March 31, 2000, a
quarterly tax distribution totaling $1,935,574 was declared and paid to the
General Partners.
Results of Operations
- ---------------------
Current quarter compared to corresponding quarter in the preceding year
- -----------------------------------------------------------------------
Net income was $21,546,740 and $5,926,368 for the three months ended March
31, 2000 and 1999, respectively. The increase was primarily due to a
$11,866,562 increase in net realized gain from equity investment sales, a
$3,017,996 increase in the net unrealized fair value of equity investments,
a $531,881 increase in interest income and a $136,516 increase in net
realized gain from venture capital limited partnerships.
For the quarter ended March 31, 2000, net realized gains from equity
investment sales of $14,105,324 primarily related to sales of shares in
Pilot Network Services, Inc. ("Pilot"), Oxford GlycoSciences Plc and
Valentis, Inc. (See Note 3.) During the same period in 1999, realized
gains of $2,238,762, related mainly to the sale of 175,000 common shares of
Pilot.
During the three months ended March 31, 2000, the increase in fair value of
equity investments of $7,005,174 was primarily due to increases in
portfolio companies in the medical industry along with increases in the
venture capital limited partnerships, partially offset by investment sales
and a decrease in the communications industry. During the same period in
1999, the increase in fair value of equity investments of $3,987,178 was
primarily due to an increase in Pilot's publicly traded market price and
the removal of a discount for selling restrictions which expired in
February 1999.
For the quarter ended March 31, 2000, interest income of $533,131 was
primarily the result of interest earned on secured notes receivable and
higher cash balances. During the same period in 1999, interest income was
$1,250.
During the quarter ended March 31, 2000 the Partnership recorded net
realized gains from venture capital limited partnership investments of
$219,012. During the same period in 1999, there were gains of $82,496.
The gains represented distributions from profits of venture capital limited
partnerships.
Total operating expenses were $297,533 and $303,754 for the quarters ended
March 31, 2000 and 1999, respectively.
Given the inherent risk associated with the business of the Partnership,
the future performance of the portfolio company investments may
significantly impact future operations.
II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) No reports on Form 8-K were filed by the Partnership during the
quarter ended March 31, 2000.
(b) Financial Data Schedule for the three months ended and as of March 31,
2000 (Exhibit 27).
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized.
TECHNOLOGY FUNDING VENTURE PARTNERS V,
AN AGGRESSIVE GROWTH FUND, L.P.
By: TECHNOLOGY FUNDING INC.
Managing General Partner
Date: May 12, 2000 By: /s/Michael R. Brenner
------------------------------------
Michael R. Brenner
Vice President
<TABLE> <S> <C>
<ARTICLE>6
<LEGEND>THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
THE FORM 10-Q AS OF MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
<MULTIPLIER>1
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<PERIOD-TYPE> 3-MOS
<INVESTMENTS-AT-COST> 24,760,874
<INVESTMENTS-AT-VALUE> 51,102,933
<RECEIVABLES> 0
<ASSETS-OTHER> 10,075
<OTHER-ITEMS-ASSETS> 14,115,339
<TOTAL-ASSETS> 65,228,347
<PAYABLE-FOR-SECURITIES> 0
<SENIOR-LONG-TERM-DEBT> 0
<OTHER-ITEMS-LIABILITIES> 1,067,837
<TOTAL-LIABILITIES> 1,067,837
<SENIOR-EQUITY> 0
<PAID-IN-CAPITAL-COMMON> 37,818,451
<SHARES-COMMON-STOCK> 400,000
<SHARES-COMMON-PRIOR> 400,000
<ACCUMULATED-NII-CURRENT> 0
<OVERDISTRIBUTION-NII> 0
<ACCUMULATED-NET-GAINS> 0
<OVERDISTRIBUTION-GAINS> 0
<ACCUM-APPREC-OR-DEPREC> 26,342,059
<NET-ASSETS> 64,160,510
<DIVIDEND-INCOME> 0
<INTEREST-INCOME> 533,131
<OTHER-INCOME> 0
<EXPENSES-NET> 366,002
<NET-INVESTMENT-INCOME> 167,129
<REALIZED-GAINS-CURRENT> 14,324,336
<APPREC-INCREASE-CURRENT> 7,055,275
<NET-CHANGE-FROM-OPS> 21,546,740
<EQUALIZATION> 0
<DISTRIBUTIONS-OF-INCOME> 0
<DISTRIBUTIONS-OF-GAINS> 0
<DISTRIBUTIONS-OTHER> 0
<NUMBER-OF-SHARES-SOLD> 0
<NUMBER-OF-SHARES-REDEEMED> 0
<SHARES-REINVESTED> 0
<NET-CHANGE-IN-ASSETS> 21,546,740
<ACCUMULATED-NII-PRIOR> 0
<ACCUMULATED-GAINS-PRIOR> 0
<OVERDISTRIB-NII-PRIOR> 0
<OVERDIST-NET-GAINS-PRIOR> 0
<GROSS-ADVISORY-FEES> 61,972
<INTEREST-EXPENSE> 0
<GROSS-EXPENSE> 368,002
<AVERAGE-NET-ASSETS> 53,387,140
<PER-SHARE-NAV-BEGIN> 103.99
<PER-SHARE-NII> 43.68
<PER-SHARE-GAIN-APPREC> 0
<PER-SHARE-DIVIDEND> 0
<PER-SHARE-DISTRIBUTIONS> 0
<RETURNS-OF-CAPITAL> 0
<PER-SHARE-NAV-END> 147.67
<EXPENSE-RATIO> 0.69
</TABLE>
